corpus callosum said:We should remember that 'biggest affinity' for a ligand to a receptor does not necessarily equate with maximum actions being exerted through this receptor; an example which is not tryptamine-related but illustrates the principal is the ability of buprenorphine to displace the more potent mu-ligand methadone from the mu receptor but the mu-mediated effects from bupe are less than that of methadone.In this case specifically buprenorphine whilst binding strongly to the mu receptor exerts a partial agonist and partial ANTAGONIST effect.
These bloody receptors we have are fascinating but they are incredibly complex when we consider them in totality; the interplay between them is the crux of the matter.Plus, its not inconceivable that exposure to other agents (via diet, the air etc) can have effects on receptor density which as a consequence muddles it all further.
Yes, fascinating!
When you give this example, are you implying that you think the same happens in the case of psychedelics and 5ht2a ?
It seems most likely that we don't know a whole lot more than we know (undiscovered receptors), and there may be a variety of different mechanisms leading to "psychedelic" effects.
Yes I agree with both of you it seems to me consciousness/brain interaction works in a highly complex and interdependent way where many different variables play a part. But if blocking one specific neuroreceptor site blocks the whole of the psychedelic effects, while this doesnt say all effects are caused in that specific pathway, but at least it tells that 5ht2a is at the very least like a "light switch" which mediates or conditions all other effects with the classic serotoninergic psychedelics, right? And then once it's through, the other pathways and effects can play their unique role everywhere else
